Zacks Investment Research upgraded shares of TransMedics Group (NASDAQ:TMDX) from a hold rating to a buy rating in a report published on Thursday, Zacks.com reports. Zacks Investment Research currently has $22.00 price target on the stock.
According to Zacks, “TransMedics Inc. is a commercial-stage medical technology company. It is engaged in transforming organ transplant therapy for end-stage organ failure patients. The company offers Organ Care System, an integrated, compact, portable preservation technology which addresses unmet need for organs for transplantation. TransMedics Inc. is headquartered in Andover, Massachusetts. “
A number of other equities research analysts have also weighed in on the stock. BidaskClub lowered shares of TransMedics Group from a buy rating to a hold rating in a report on Saturday, February 1st. Cowen reduced their price objective on shares of TransMedics Group from $40.00 to $28.00 and set an outperform rating on the stock in a report on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of Buy and an average target price of $30.25.
In other news, insider Tamer I. Khayal sold 5,000 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $20.02, for a total value of $100,100.00. Following the sale, the insider now directly owns 51,076 shares in the company, valued at approximately $1,022,541.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Several institutional investors and hedge funds have recently made changes to their positions in TMDX. Credit Suisse AG raised its holdings in shares of TransMedics Group by 47.6% in the 4th quarter. Credit Suisse AG now owns 1,131,845 shares of the company’s stock valued at $21,516,000 after purchasing an additional 365,271 shares in the last quarter. Vanguard Group Inc. acquired a new stake in TransMedics Group during the 2nd quarter worth $8,957,000. Emerald Advisers LLC raised its stake in TransMedics Group by 116.6% during the 4th quarter. Emerald Advisers LLC now owns 451,542 shares of the company’s stock worth $8,584,000 after acquiring an additional 243,034 shares in the last quarter. Sandhill Capital Partners LLC raised its stake in TransMedics Group by 48.4% during the 4th quarter. Sandhill Capital Partners LLC now owns 736,175 shares of the company’s stock worth $13,995,000 after acquiring an additional 240,149 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust raised its stake in TransMedics Group by 118.8% during the 4th quarter. Emerald Mutual Fund Advisers Trust now owns 429,868 shares of the company’s stock worth $8,172,000 after acquiring an additional 233,358 shares in the last quarter. Institutional investors and hedge funds own 71.13% of the company’s stock.
TransMedics Group Company Profile
TransMedics, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation.
See Also: How to identify percentage decliners
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.